Matt Gline, Roivant CEO (courtesy Roivant)
November 27, 2023 10:48 AM EST
R&D

Roivan­t's JAK/TYK2 in­hibitor fails PhII lu­pus study

Max Gelman

Senior Editor

Roivant re­port­ed Mon­day morn­ing that a pro­gram li­censed from Pfiz­er failed a Phase II lu­pus tri­al and that it would end de­vel­op­ment in the con­di­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Kennedy is con­firmed to lead HHS, putting an­ti-vac­cine ad­vo­cate and drug in­dus­try skep­tic atop US health ...

Neumo­ra shakes up C-suite a month af­ter de­pres­sion drug fails first Phase 3 tri­al

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Sanofi faces $250M charge af­ter J&J-part­nered vac­cine flunks late-stage test

Agios’ Pyrukynd suc­ceeds in key tri­al of rare red blood cell dis­or­der in kids

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times